{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:08Z","timestamp":1740108128222,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00347-021-01474-6","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T07:02:51Z","timestamp":1628146971000},"page":"258-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Erste Erfahrungen mit Brolucizumab bei neovaskul\u00e4rer altersabh\u00e4ngiger Makuladegeneration und Therapierefrakt\u00e4rit\u00e4t unter der bisherigen Anti-VEGF-Therapie","Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-8673","authenticated-orcid":false,"given":"Marius","family":"Book","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Rothaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Faatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gutfleisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Spital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pauleikhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"1474_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong\u00a0WL, Su\u00a0X, Li\u00a0X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a\u00a0systematic review and meta-analysis. Lancet Glob Health 2:106\u2013116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"1474_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/637316","author":"YG Park","year":"2012","unstructured":"Park\u00a0YG, Rhu\u00a0HW, Kang\u00a0S et al (2012) New approach of anti-VEGF agents for age-related macular degeneration. J\u00a0Ophthalmol. https:\/\/doi.org\/10.1155\/2012\/637316","journal-title":"J Ophthalmol"},{"key":"1474_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld\u00a0PJ, Brown\u00a0DM, Heier\u00a0JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N\u00a0Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"1474_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth\u00a0U, Chong\u00a0V, Loewenstein\u00a0A et al (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144\u20131167. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702","journal-title":"Br J Ophthalmol"},{"key":"1474_CR5","doi-asserted-by":"publisher","unstructured":"Deutsche Ophthalmologische Gesellschaft (DOG)., Retinologische Gesellschaft e.\u202fV. (RG). & Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA). Stellungnahme der DOG, der RG und des BVA zur Anti-VEGF-Therapie bei der neovaskul\u00e4ren altersabh\u00e4ngigen Makuladegeneration. Ophthalmologe 117. 200; 746\u2013754. https:\/\/doi.org\/10.1007\/s00347-020-01117-2","DOI":"10.1007\/s00347-020-01117-2"},{"key":"1474_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"IVAN study investigators, Chakravarthy\u00a0U, Harding\u00a0SP, Rogers\u00a0CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2\u2011year findings of the IVAN randomised controlled trial. Lancet 382:1258\u20131267. https:\/\/doi.org\/10.1016\/S0140-6736(13)61501-9","journal-title":"Lancet"},{"key":"1474_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Martin\u00a0DF, Maguire\u00a0MG, Fine\u00a0SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053","journal-title":"Ophthalmology"},{"key":"1474_CR8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1097\/IAE.0000000000000134","volume":"34","author":"F Abedi","year":"2014","unstructured":"Abedi\u00a0F, Wickremasinghe\u00a0S, Islam\u00a0AF et al (2014) Anti-VEGF treatment in neovascular age-related macular degeneration: a\u00a0treat-and-extend protocol over 2\u00a0years. Retina 34:1531\u20131538. https:\/\/doi.org\/10.1097\/IAE.0000000000000134","journal-title":"Retina"},{"key":"1474_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","volume":"3","author":"PG Traine","year":"2019","unstructured":"Traine\u00a0PG, Pfister\u00a0IB, Zandi\u00a0S et al (2019) Long-term outcome of Intravitreal aflibercept treatment for neovascular age-related macular degeneration using a\u00a0\u201ctreat-and-extend\u201d regimen. Ophthalmol Retina 3:393\u2013399. https:\/\/doi.org\/10.1016\/j.oret.2019.01.018","journal-title":"Ophthalmol Retina"},{"key":"1474_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/eye.2014.258","volume":"29","author":"C Gianniou","year":"2015","unstructured":"Gianniou\u00a0C, Dirani\u00a0A, Ferrini\u00a0W et al (2015) Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye 29:342\u2013349. https:\/\/doi.org\/10.1038\/eye.2014.258","journal-title":"Eye"},{"key":"1474_CR11","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/bjophthalmol-2013-304556","volume":"98","author":"I Mantel","year":"2014","unstructured":"Mantel\u00a0I, Niderprim\u00a0SA, Gianniou\u00a0C et al (2014) Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol 98:1192\u20131196. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304556","journal-title":"Br J Ophthalmol"},{"key":"1474_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"HAWK and HARRIER Study Investigators, Dugel\u00a0PU, Koh\u00a0A, Ogura\u00a0Y et al (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"1474_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel\u00a0PU, Singh\u00a0RP, Koh\u00a0A et al (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128:89\u201399. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.028","journal-title":"Ophthalmology"},{"key":"1474_CR14","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto\u00a0H, Hoshino\u00a0J, Mukai\u00a0R et al (2021) Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep 11:6759. https:\/\/doi.org\/10.1038\/s41598-021-86014-7","journal-title":"Sci Rep"},{"key":"1474_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","volume":"35","author":"A Sharma","year":"2021","unstructured":"Sharma\u00a0A, Kumar\u00a0N, Parachuri\u00a0N et al (2021) Brolucizumab-early real-world experience: BREW study. Eye (Lond) 35:1045\u20131047. https:\/\/doi.org\/10.1038\/s41433-020-1111-x","journal-title":"Eye (Lond)"},{"key":"1474_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318672","author":"LM Bulirsch","year":"2021","unstructured":"Bulirsch\u00a0LM, Sa\u00dfmannshausen\u00a0M, Nadal\u00a0J et al (2021) Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318672","journal-title":"Br J Ophthalmol"},{"key":"1474_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/IMCRJ.S252260","volume":"13","author":"J Avaylon","year":"2020","unstructured":"Avaylon\u00a0J, Lee\u00a0S, Gallemore\u00a0RP (2020) Case series on initial responses to Intravitreal brolucizumab in patients with recalcitrant chronic wet age-related macular degeneration. Int Med Case Rep\u00a0J 13:145\u2013152. https:\/\/doi.org\/10.2147\/IMCRJ.S252260","journal-title":"Int Med Case Rep J"},{"key":"1474_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","volume":"139","author":"AB Enr\u00edquez","year":"2021","unstructured":"Enr\u00edquez\u00a0AB, Baumal\u00a0CR, Crane\u00a0AM et al (2021) Early experience with brolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol 139:441\u2013448. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.7085","journal-title":"JAMA Ophthalmol"},{"issue":"202","key":"1474_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00347-021-01321-8","volume":"118","author":"FG Holz","year":"2021","unstructured":"Holz FG, Heinz C, Wolf A et al (2021) Intraokulare Entz\u00fcndungen bei Brolucizumab-Anwendung: Patientenmanagement \u2013 Diagnose \u2013 Therapie. Ophthalmologe 118(202):248\u2013256. https:\/\/doi.org\/10.1007\/s00347-021-01321-8","journal-title":"Ophthalmologe"},{"key":"1474_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s\u00a0J, Srivastava\u00a0SK, Jaffe\u00a0GJ et al (2020) Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011","journal-title":"Ophthalmology"},{"key":"1474_CR21","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","volume":"120","author":"GJ Jaffe","year":"2013","unstructured":"Jaffe\u00a0GJ, Martin\u00a0DF, Toth\u00a0CA et al (2013) Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:1860\u20131870. https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.073","journal-title":"Ophthalmology"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01474-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-021-01474-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-021-01474-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T09:05:32Z","timestamp":1646730332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-021-01474-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1007\/s00347-021-01474-6","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"type":"print","value":"0941-293X"},{"type":"electronic","value":"1433-0423"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"26 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Book, M.\u00a0Ziegler, K.\u00a0Rothaus, H.\u00a0Faatz, M.\u00a0Gutfleisch, G.\u00a0Spital, A.\u00a0Lommatzsch und D.\u00a0Pauleikhoff geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}